Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230017/S010

PulseSelect Pulse Field Ablation (PFA) Catheter

Medtronic, Inc. · Decision date Apr 13, 2026

FDA DECISIONP230017/S010

What did the FDA approve?

FDA records P230017/S010 as a supplement to PMA P230017, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Apr 13, 2026.

FDA approval order statement

approval for a manufacturing site located at Parkmore Business Park, West, Ballybrit, Galway, Ireland
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Apr 13, 2026
FDA change category
Location Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P230017/S010
Regulatory pathway
PMA supplement
Product code
QZI
Decision code
APPR
Decision date
Apr 13, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Product code
QZI
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P230017/S008 · Related supplement

    PulseSelect Pulsed Field Ablation (PFA) system

  2. P230017/S009 · Related supplement

    PulseSelect Pulsed Field Ablation (PFA) system

  3. P230017/S010 received

    Application receipt date recorded by FDA.

  4. P230017/S010 · FDA decision

    Normal 180 Day Track No User Fee

  5. P230017/S011 · Related supplement

    PulseSelect Pulse Field Ablation (PFA) Catheter

Timeline entries are records held by MedtechLedger for P230017. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230017

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementOct 8, 2025FDA
Medtronic, Inc.PMA supplementFeb 17, 2026FDA
Medtronic, Inc.PMA supplementJun 30, 2026FDA

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA
Kardium, Inc.PMA supplementOct 27, 2026FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records